Kauffman C A, Terpenning M S, He X, Zarins L T, Ramsey M A, Jorgensen K A, Sottile W S, Bradley S F
Division of Infectious Diseases, Department of Veterans Affairs Medical Center, Ann Arbor, Michigan 48105.
Am J Med. 1993 Apr;94(4):371-8. doi: 10.1016/0002-9343(93)90147-h.
To assess the impact of the use of mupirocin ointment on colonization, transmission, and infection with methicillin-resistant Staphylococcus aureus (MRSA) in a long-term-care facility.
All 321 residents of a Veterans Affairs long-term-care facility from June 1990 through June 1991 were studied for MRSA colonization and infection. MRSA-colonized patients received mupirocin ointment to nares in the first 7 months and to nares and wounds in the second 5 months. The effect of mupirocin use on MRSA colonization and infection was monitored. All S. aureus strains isolated were tested for the development of resistance to mupirocin.
A total of 65 patients colonized with MRSA received mupirocin ointment. Mupirocin rapidly eliminated MRSA at the sites treated in most patients by the end of 1 week. Weekly maintenance mupirocin was not adequate to prevent recurrences--40% of patients had recurrence of MRSA. Overall, MRSA colonization in the facility, which was 22.7% +/- 1% prior to the use of mupirocin, did not change when mupirocin was used in nares only (22.2% +/- 2.1%), but did decrease to 11.5% +/- 1.8% when mupirocin was used in nares and wounds. Although colonization decreased, roommate-to-roommate transmission and MRSA infection rates, low to begin with, did not change when mupirocin was used. Mupirocin-resistant MRSA strains were isolated in 10.8% of patients.
Mupirocin ointment is effective at decreasing colonization with MRSA. However, constant surveillance was required to identify patients colonized at admission or experiencing recurrence of MRSA during maintenance treatment. Long-term use of mupirocin selected for mupirocin-resistant MRSA strains. Mupirocin should be saved for use in outbreak situations, and not used over the long term in facilities with endemic MRSA colonization.
评估莫匹罗星软膏对长期护理机构中耐甲氧西林金黄色葡萄球菌(MRSA)定植、传播及感染的影响。
对1990年6月至1991年6月期间一家退伍军人事务长期护理机构的321名居民进行MRSA定植和感染研究。MRSA定植患者在最初7个月接受莫匹罗星软膏涂抹鼻腔,后5个月涂抹鼻腔和伤口。监测使用莫匹罗星对MRSA定植和感染的影响。对所有分离出的金黄色葡萄球菌菌株进行莫匹罗星耐药性检测。
共有65例MRSA定植患者接受了莫匹罗星软膏治疗。在大多数患者中,莫匹罗星在1周结束时迅速清除了治疗部位的MRSA。每周维持使用莫匹罗星不足以预防复发——40%的患者出现MRSA复发。总体而言,该机构中MRSA定植率在使用莫匹罗星前为22.7%±1%,仅在鼻腔使用莫匹罗星时未改变(22.2%±2.1%),但在鼻腔和伤口使用莫匹罗星时降至11.5%±1.8%。尽管定植率下降,但使用莫匹罗星时,室友间传播和MRSA感染率(起初较低)并未改变。10.8%的患者分离出耐莫匹罗星的MRSA菌株。
莫匹罗星软膏在降低MRSA定植方面有效。然而,需要持续监测以识别入院时定植或在维持治疗期间出现MRSA复发的患者。长期使用莫匹罗星会筛选出耐莫匹罗星的MRSA菌株。莫匹罗星应留作爆发情况时使用,而不应在有MRSA地方性定植的机构中长期使用。